Análisis Argos
CRS
CRSCara
Carpenter Technology Corporation · Industrials
US$ 597.24
precio al 2026-07-04
Valor justo Argos*
Sin estimar
vs. su valor justo
Sin estimar
Score Argos
54/100
LA RESPUESTA
El mercado le pide crezca 60% al año — más de lo que ha demostrado (9%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
Las ganancias crecieron 102% el último año.
Retorno sobre el capital alto (18%).
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
!Venta significativa de insiders en el último trimestre.
VALOR1/6FUTURO3/6PASADO5/6SALUD4/6DIVIDENDO2/6
El Iris de calidad
VALOR1/6FUTURO3/6PASADO5/6SALUD4/6DIVIDENDO2/6
ValorCotiza por encima de su valor justo
FuturoCrecimiento moderado
PasadoFundamentales sólidos y sostenidos
SaludBalance fuerte, deuda controlada
DividendoRetorno al accionista moderado
Score Argos54de 100Cara
Ingresos4%
US$ 2.9 B
Margen operativo55%
18.1%
Flujo de caja libre61%
US$ 0.3 B
Deuda neta
US$ 0.4 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 29.7B
P/E78.9x
EV/EBITDA45.5x
FCF yield1%
ROIC18.2%
Margen operativo18.1%
Crecim. ingresos+4.3%/año
Piotroski F7/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

zacks.com · 3 jul
Will Carpenter (CRS) Beat Estimates Again in Its Next Earnings Report?
Carpenter (CRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
globenewswire.com · 1 jul
Carpenter Technology Announces Conference Call and Webcast
PHILADELPHIA, July 01, 2026 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) plans to host a conference call and webcast on Thursday, July 30, 2026 at 10:00 a.m. ET to discuss the results of operations for the fourth quarter of fiscal year 2026, ended June 30, 2026.
zacks.com · 30 jun
3 Reasons Why Growth Investors Shouldn't Overlook Carpenter (CRS)
Carpenter (CRS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
zacks.com · 26 jun
Are You Looking for a Top Momentum Pick? Why Carpenter Technology (CRS) is a Great Choice
Does Carpenter Technology (CRS) have what it takes to be a top stock pick for momentum investors? Let's find out.
newsfilecorp.com · 23 jun
DelphX Capital Markets Provides Corporate Update on Structured Income Program and CRS Commercialization
Advancing financing partner alignment for BTC Structured Income Program; in active discussions on a pilot transaction with a major U.S. insurer for Credit Rating Securities Toronto, Ontario and New York, New York--(Newsfile Corp. - June 23, 2026) - DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB: DPXCF)  ("DelphX" or the "Company") today provided a corporate update on two of its principal commercialization workstreams. BTC Structured Income Program - Financing Partner Alignment The Company is pleased to report that it has finalized and executed a definitive agreement with a leading global digital asset lender - recognized as one of the most active and established credit providers in the cryptocurrency sector - for the senior secured lending facility that forms the foundational layer of capital for the Company's BTC Structured Income Program (the "Program").
zacks.com · 18 jun
Carpenter Technology (CRS) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
proactiveinvestors.co.uk · 16 jun
Poolbeg's European patent win bolsters partnering case before summer trial data, says Cavendish
Shares in PPoolbeg Pharma PLC (AIM:POLB) rose 3% to 7.8p on Tuesday, taking their gain for the year to date to around 100%, after the drug developer secured a key European patent. The European Patent Office has agreed to grant a patent covering POLB 001, Poolbeg's experimental treatment for preventing cytokine release syndrome (CRS), a dangerous immune reaction triggered by some cancer immunotherapies.
globenewswire.com · 15 jun
Supporting the Mission: Catholic Relief Services Chooses Adstra as a Fundraising Partner
PRINCETON, N.J., June 15, 2026 (GLOBE NEWSWIRE) -- Adstra Nonprofit today announced a strategic partnership with Catholic Relief Services (CRS), one of the world's leading humanitarian organizations.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.